[VIRTUAL] NEOpredict-Lung: A phase II study of neoadjuvant immunotherapy with nivolumab or nivolumab and Relatlimab in patients with primarily resectable, non-small cell lung cancer

[VIRTUAL] QUAZAR AML-001 Maintenance Therapy Study: Results of an international, randomized, double-blind, placebo-controlled phase 3 study of oral CC-486 in patients with acute myeloid leukemia (AML) in first remission

[VIRTUAL] KarMMa-RW: A real-world study provides data on everyday clinical treatment in repeatedly pretreated patients with relapsed and refractory multiple myeloma (RRMM) in comparison to the results of the KarMMa study

[VIRTUAL] Immunomonitoring under blinatumoma therapy in pediatric patients with BCP-ALL within the AIEOP-BFM 2017 study - an interim analysis

[VIRTUAL] Cassiopeia: A phase 2 study to evaluate the efficacy and safety of tisagenlecleucel as first-line therapy in high-risk children and young adults with B-cell acute lymphoblastic leukemia who are MRD positive at the end of consolidation

[VIRTUAL] Phase I study of MB-CART2019.1, a novel CD20 and CD19 tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

[VIRTUAL] RE-MIND: A Comparison of Tafasitamab + Lenalidomde (L-MIND) vs Lenalidomide Monotherapy ('Real World' Data) in Patients with Relapsed / Refractory Diffuse Large B-Cell Lymphoma

[VIRTUAL] Correlation of bridging therapy (BT) and lymphodepleting chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed / refractory diffuse large B-cell lymphoma (r / r DLBCL) treated with Tisagenlecleucel

[VIRTUAL] Long-term results of the phase II L-MIND study: tafasitamab (MOR208) + lenalidomide in patients with relapsed / refractory diffuse large B-cell lymphoma

[VIRTUAL] ENGOT-EN6 / GOG-3031 / NSGO-RUBY: A randomized, double-blind, multicenter phase III study with dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in relapsed or primarily advanced endometrial cancer (EC)

[VIRTUAL] Capmatinib in patients with METex14-mutated or highly MET-amplified advanced non-small cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study

[VIRTUAL] Durvalumab with / without bevacizumab as adjuvant therapy in HCC patients with a high risk of relapsing after curative therapy: EMERALD-2

[VIRTUAL] Perioperative chemotherapy with gemcitabine plus cisplatin versus direct radical liver resection for gallbladder carcinoma after simple cholecystectomy or before radical resection for BTC - a phase III study based on the "Central Register of Incidental Gallbladder Carcinoma"

[VIRTUAL] Trifluridine / tipiracil in patients with metastatic colorectal cancer in routine clinical practice in Germany: interim results of the non-interventional study TACTIC